Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Kidney Cancer - Pipeline Review, Q1 2011 by GlobalMarketsDirect

VIEWS: 5 PAGES: 142

Kidney Cancer - Pipeline Review, Q1 2011 Summary Global Markets Direct’s, 'Kidney Cancer - Pipeline Review, Q1 2011', provides an overview of the Kidney Cancer therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer. 'Kidney Cancer - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - A snapshot of the global therapeutic scenario for Kidney Cancer. - A review of the Kidney Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Kidney Cancer pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Kidney Cancer. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devis

More Info
									                     Kidney Cancer - Pipeline Review, Q1 2011
                                                                                          Reference Code: GMDHC431IDB

                                                                                          Publication Date: January 2011




Kidney Cancer – Pipeline Review, Q1 2011                                                                              GMDHC431IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                         Page(1)
Kidney Cancer – Pipeline Review, Q1 2011




Ta b le o f Co n te n ts
Table of Contents                                                                                              2
List of Tables                                                                                                 7
List of Figures                                                                                                9
Introduction                                                                                                  10
     Global Markets Direct Report Coverage                                                                    10
Kidney Cancer Overview                                                                                        11
Therapeutics Development                                                                                      12
     An Overview of Pipeline Products for Kidney Cancer                                                       12
Kidney Cancer Therapeutics under Development by Companies                                                     14
Kidney Cancer Therapeutics under Investigation by Universities/Institutes                                     18
Late Stage Products                                                                                           27
     Comparative Analysis                                                                                     27
Mid Clinical Stage Products                                                                                   28
     Comparative Analysis                                                                                     28
Early Clinical Stage Products                                                                                 29
     Comparative Analysis                                                                                     29
Discovery and Pre-Clinical Stage Products                                                                     30
     Comparative Analysis                                                                                     30
Companies Involved in Kidney Cancer Therapeutics Development                                                  31
     Bristol-Myers Squibb Company                                                                             31
     Genzyme Corporation                                                                                      31
     Johnson & Johnson                                                                                        32
     F. Hoffmann-La Roche Ltd.                                                                                32
     Kyowa Hakko Kirin Co., Ltd.                                                                              33
     Abbott Laboratories                                                                                      33
     Amgen Inc.                                                                                               34
     AstraZeneca PLC                                                                                          34
     Eli Lilly and Company                                                                                    35
     GlaxoSmithKline plc                                                                                      35
     Merck & Co., Inc.                                                                                        36
     Oxford BioMedica plc                                                                                     36
     Takeda Pharmaceutical Company Limited                                                                    37
     Light Sciences Oncology, Inc.                                                                            37
     Prolexys Pharmaceuticals, Inc.                                                                           38
     Neurocrine Biosciences, Inc.                                                                             38
     ZIOPHARM Oncology, Inc.                                                                                  39
     Novartis AG                                                                                              39
     Astellas Pharma Inc.                                                                                     40
     Eisai Co., Ltd.                                                                                          40
     Pfizer Inc.                                                                                              41
     Exelixis, Inc.                                                                                           41
     VasGene Therapeutics, Inc.                                                                               42
     Celgene Corporation                                                                                      42
     Bayer AG                                                                                                 43
     3SBio Inc.                                                                                               43
     Celldex Therapeutics, Inc.                                                                               44
     Active Biotech AB                                                                                        44


Kidney Cancer – Pipeline Review, Q1 2011                                                  GMDHC431IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                             Page(2)
Kidney Cancer – Pipeline Review, Q1 2011


     AEterna Zentaris Inc.                                                                                    45
     Northwest Biotherapeutics, Inc.                                                                          45
     Cleveland BioLabs, Inc.                                                                                  46
     Oncothyreon Inc                                                                                          46
     Patrys Limited                                                                                           47
     ARQULE, INC                                                                                              47
     Dendreon Corporation                                                                                     48
     Thallion Pharmaceuticals Inc.                                                                            48
     Antisoma plc                                                                                             49
     TapImmune Inc.                                                                                           49
     OncoTherapy Science, Inc.                                                                                50
     Innate Pharma SA                                                                                         50
     Protox Therapeutics Inc.                                                                                 51
     Wilex AG                                                                                                 51
     Memorial Sloan Kettering Cancer Center                                                                   52
     Antisoma Research Limited                                                                                53
     Glycotope GmbH                                                                                           53
     ERYtech Pharma                                                                                           53
     immatics biotechnologies GmbH                                                                            54
     Curacyte AG                                                                                              54
     AgrenVec, S.L.                                                                                           55
     Gene Signal International SA.                                                                            55
     MacroGenics, Inc.                                                                                        56
     Pivotal BioSciences, Inc.                                                                                56
     Neotropix, Inc.                                                                                          57
     Jennerex Biotherapeutics, Inc.                                                                           57
     Intarcia Therapeutics, Inc.                                                                              58
     Endocyte, Inc.                                                                                           58
     Pharminox Limited                                                                                        59
     Syndax Pharmaceuticals, Inc.                                                                             59
     OncoMune, LLC                                                                                            60
     Esperance Pharmaceuticals, Inc.                                                                          60
     Welichem Biotech Inc.                                                                                    61
     Tigris Pharmaceuticals, Inc.                                                                             61
     KAHR medical Ltd.                                                                                        62
     Advanced Cancer Therapeutics                                                                             62
     Medical Enzymes AG                                                                                       63
     Polaris Group                                                                                            63
     IkerChem S.L.                                                                                            63
     Theradex Systems, Inc.                                                                                   64
     Agennix AG                                                                                               64
     Immunovative Therapies, Ltd.                                                                             65
     Hoosier Oncology Group, Inc.                                                                             65
Universities/Institutes Involved in Kidney Cancer Therapeutics Development                                    66
Kidney Cancer Therapeutics Assessment                                                                         87
     Assessment by Monotherapy Products                                                                       87
     Assessment by Combination Products                                                                       88
     Assessment by Route of Administration                                                                    89




Kidney Cancer – Pipeline Review, Q1 2011                                                  GMDHC431IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                       Page(3)
Kidney Cancer – Pipeline Review, Q1 2011


     Assessment by Molecule Type                                                                               91
Late Stage Drug Profiles – Companies                                                                           93
     ANYARA - Drug Profile                                                                                    93
          Product Description                                                                                 93
          Mechanism of Action                                                                                 93
          R&D Progress                                                                                         93
     ANYARA + Interferon Alpha - Drug Profile                                                                 94
          Product Description                                                                                 94
          Mechanism of Action                                                                                 94
          R&D Progress                                                                                        94
     Avastin + Roferon - Drug Profile                                                                         95
          Product Description                                                                                 95
          Mechanism of Action                                                                                 95
          R&D Progress                                                                                        95
     Axitinib - Drug Profile                                                                                   96
          Product Description                                                                                 96
          Mechanism of Action                                                                                 96
          R&D Progress                                                                                        96
     Interferon Alfa + CCI-779 - Drug Profile                                                                 97
          Product Description                                                                                 97
          Mechanism of Action                                                                                 97
          R&D Progress                                                                                        97
     NuLeusin - Drug Profile                                                                                   98
          Product Description                                                                                 98
          Mechanism of Action                                                                                 98
          R&D Progress                                                                                        98
     Rencarex - Drug Profile                                                                                  99
          Product Description                                                                                 99
          Mechanism of Action                                                                                 99
          R&D Progress                                                                                        99
     Tivozanib - Drug Profile                                                                                 100
          Product Description                                                                                 100
          Mechanism of Action                                                                                 100
          R&D Progress                                                                                        100
     TroVax + IL-2 - Drug Profile                                                                             102
          Product Description                                                                                 102
          Mechanism of Action                                                                                 102
          R&D Progress                                                                                        102
Late Stage Drug Profiles – Universities/Institutes                                                            103
     Aldesleukin + Interferon - Drug Profile                                                                  103
          Product Description                                                                                 103
          Mechanism of Action                                                                                 103
          R&D Progress                                                                                        103
     aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile                                  105
          Product Description                                                                                 105
          Mechanism of Action                                                                                 105
          R&D Progress                                                                                        106
     Aldesleukin for Kidney Cancer - Drug Profile                                                             107




Kidney Cancer – Pipeline Review, Q1 2011                                                  GMDHC431IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                       Page(4)
Kidney Cancer – Pipeline Review, Q1 2011


          Product Description                                                                                                                107
          Mechanism of Action                                                                                                                107
          R&D Progress                                                                                                                       107
     bevacizumab + recombinant interferon alfa - Drug Profile                                                                                108
          Product Description                                                                                                                108
          Mechanism of Action                                                                                                                108
          R&D Progress                                                                                                                       108
     Cisplatin + Gemcitabine + Paclitaxel - Drug Profile                                                                                     109
          Product Description                                                                                                                109
          Mechanism of Action                                                                                                                109
          R&D Progress                                                                                                                       109
     Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate - Drug Profile              111
          Product Description                                                                                                                111
          Mechanism of Action                                                                                                                111
          R&D Progress                                                                                                                       112
     dactinomycin + doxorubicin + vincristine + radiation therapy - Drug Profile                                                             113
          Product Description                                                                                                                113
          Mechanism of Action                                                                                                                113
          R&D Progress                                                                                                                       113
     Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile
                                                                                                                                             114
          Product Description                                                                                                                114
          Mechanism of Action                                                                                                                114
          R&D Progress                                                                                                                       115
     Doxorubicin hydrochloride - Drug Profile                                                                                                117
          Product Description                                                                                                                117
          Mechanism of Action                                                                                                                117
          R&D Progress                                                                                                                       117
     Everolimus - Drug Profile                                                                                                               118
          Product Description                                                                                                                118
          Mechanism of Action                                                                                                                118
          R&D Progress                                                                                                                       118
     Everolimus + Bevacizumab - Drug Profile                                                                                                 119
          Product Description                                                                                                                119
          Mechanism of Action                                                                                                                119
          R&D Progress                                                                                                                       119
     Interferon-alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile                                                                        120
          Product Description                                                                                                                120
          Mechanism of Action                                                                                                                120
          R&D Progress                                                                                                                       120
     Pegylated interferon alfa - Drug Profile                                                                                                122
          Product Description                                                                                                                122
          Mechanism of Action                                                                                                                122
          R&D Progress                                                                                                                       122
     Recombinant interferon alfa + Isotretinoin - Drug Profile                                                                               123
          Product Description                                                                                                                123
          Mechanism of Action                                                                                                                123
          R&D Progress                                                                                                                       123
     recombinant interferon alfa + thalidomide - Drug Profile                                                                                124


Kidney Cancer – Pipeline Review, Q1 2011                                                                      GMDHC431IDB / Pub JAN 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                      Page(5)
Kidney Cancer – Pipeline Review, Q1 2011


          Product Description                                                                                                              124
          Mechanism of Action                                                                                                              124
          R&D Progress                                                                                                                     124
     Sorafenib - Drug Profile                                                                                                              126
          Product Description                                                                                                              126
          Mechanism of Action                                                                                                              126
          R&D Progress                                                                                                                     126
     Sorafenib - Drug Profile                                                                                                              127
          Product Description                                                                                                              127
          Mechanism of Action                                                                                                              127
          R&D Progress                                                                                                                     127
     Sorafenib Tosylate - Drug Profile                                                                                                     129
          Product Description                                                                                                              129
          Mechanism of Action                                                                                                              129
          R&D Progress                                                                                                                     129
     sorafenib tosylate, sunitinib malate - Drug Profile                                                                                   130
          Product Description                                                                                                              130
          Mechanism of Action                                                                                                              130
          R&D Progress                                                                                                                     130
     Sunitinib - Drug Profile                                                                                                              132
          Product Description                                                                                                              132
          Mechanism of Action                                                                                                              132
          R&D Progress                                                                                                                     132
     sunitinib - Drug Profile                                                                                                              133
          Product Description                                                                                                              133
          Mechanism of Action                                                                                                              133
          R&D Progress                                                                                                                     133
Discontinued Products                                                                                                                      134
     Kidney Cancer - Featured News                                                                                                         135
          Oct 14, 2010: Oxford BioMedica Announces Publication Of TroVax Phase III Results In Metastatic Renal Cancer In Clinical Cancer
          Research                                                                                                                         135
          Oct 07, 2010: Bayer And Onyx Announce Nexavar Data Presentations At 35th European Society For Medical Oncology Congress          135
          Sep 01, 2010: Agensys Initiates Phase I Clinical Trial Of AGS-16M8F For Renal Cancer                                             136
          Aug 12, 2010: AVEO Achieves Enrollment Target Ahead Of Schedule For Pivotal Phase III Trial Of Tivozanib                         137
          Aug 10, 2010: GenSpera Receives Additional Patent For Oncology Drug, G-202                                                       138
          Jul 12, 2010: Threshold Presents Preclinical Results On TH-302 At AACR Translational Cancer Medicine Meeting                     138
          Jun 05, 2010: Immatics Announces Phase II Results With Its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced Renal Cell
          Carcinoma at ASCO                                                                                                               139
          
								
To top